In our meta-analysis, all the treatments improved NAFLD disease by lowering levels of liver enzymes, including ALT, AST, ALP, and GGT, as shown in Figures 6, 7. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.